METHOD FOR PREDICTION OF RISK OF LETHAL OUTCOME OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AT HOSPITAL STAGE Russian patent published in 2025 - IPC G01N33/68 G01N33/49 A61B5/107 A61B5/00 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to cardiology and endocrinology, and can be used for prediction of risk of lethal outcome of acute myocardial infarction in patients with type 2 diabetes mellitus at hospital stage. Patient’s peripheral blood and high-sensitivity C-reactive protein (hsCRP) are sampled and clinically analysed. Body weight index (BWI), kg/m², is determined, the number of implanted coronary stents (Nst) is taken into account. Patient’s blood cell composition is determined on the third day after the primary percutaneous coronary intervention: neutrophil count, ×10⁹/l, lymphocyte count, ×10⁹/l, thrombocyte count, ×10⁹/l, monocyte count, ×10⁹/l. Cell indices of systemic inflammation – neutrophil-lymphocyte ratio (NLR), systemic immune inflammation index (SII), systemic immune-inflammatory response index (SIRI) are calculated. Blood level of highly sensitive C-reactive protein is determined at admission and on the third day after primary percutaneous coronary intervention, mg/l. Degree of its change is calculated (ΔhsCRP) equal to the difference between blood levels of hsCRP on the third day after the primary percutaneous coronary intervention and at admission. Prognostic coefficient P is determined by formula:

where: P is a prognostic coefficient; b₀ is constant=-18.592; b₁ is non-standardized coefficient=0.041; b₂ is non-standardized coefficient=2.168; b₃ is non-standardized coefficient=-0.006; b₄ is non-standardized coefficient=0.326; b₅ is non-standardized coefficient=0.293; b₆ is non-standardized coefficient=1.882; e is base of natural logarithm ~2.72; ΔhsCRP is degree of change of highly sensitive C-reactive protein after primary percutaneous coronary intervention; NLR is neutrophil-lymphocyte ratio on the third day after primary percutaneous coronary intervention; SII is the systemic immune inflammation index on the third day after the primary percutaneous coronary intervention; SIRI is the systemic immune-inflammatory response index on the third day after the primary percutaneous coronary intervention; BWI – body weight index; Nst. – number of stents implanted in coronary arteries during primary percutaneous coronary intervention. If P is more than or equal to 0.159, a high risk of fatal outcome is predicted, and if P is less than 0.159, a low risk is predicted.

EFFECT: method provides the possibility of increasing the sensitivity, specificity and accuracy of predicting the fatal outcome of acute myocardial infarction in a patient with type 2 diabetes mellitus at the hospital stage after myocardial revascularization in the volume of primary percutaneous coronary intervention by clinical analysis of peripheral blood values and determination of the level of highly sensitive C-reactive protein in patient's blood serum.

1 cl, 2 ex